FDA Skeptical Of Maintenance Claims For Centacor's Remicade In Pediatric Ulcerative Colitis
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency accepts 8-week efficacy, but says long-term data is sparse for the tumor necrosis factor inhibitor, which goes before the Gastrointestinal Drugs Advisory Committee July 21.
You may also be interested in...
Pediatric IBD Studies Should Assess Disease Activity, Panel Says
Clinicians tell FDA that focusing solely on symptoms as an endpoint for pediatric ulcerative colitis and Crohn’s disease ignores the long-term deleterious effects of inflammation. Panel stresses the need to include growth as an endpoint and to conduct pediatric studies earlier.
FDA Panel Rejects Steroid-Sparing Claim For Remicade In Pediatric Ulcerative Colitis
Extrapolation from adult data does not work in this case and there is insufficient supporting pediatric data, the Gastrointestinal Drugs Advisory Committee concluded July 21.
FDA Panel Rejects Steroid-Sparing Claim For Remicade In Pediatric Ulcerative Colitis
Extrapolation from adult data does not work in this case and there is insufficient supporting pediatric data, the Gastrointestinal Drugs Advisory Committee concluded July 21.